Torrent Pharmaceuticals Ltd (TORNTPHARM) is currently trading at 4,741.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Torrent Pharmaceuticals is an India-focused pharmaceutical company specializing in chronic and sub-chronic therapies, including cardiovascular, CNS, diabetes, gastrointestinal, vitamins and dermatology, with operations across India, the United States, Brazil, Germany and other international markets. The July 2026 merger with JB Chemicals materially expanded Torrent Pharmaceuticals’ scale, taking the combined India field force to 9,100 representatives. Although integration temporarily slowed JB’s sales, management said cost synergies are ahead of schedule and India revenue synergies should increasingly emerge from cross-selling and broader territory coverage. Torrent Pharmaceuticals delivered consolidated Q2 FY27 revenue of INR4,979 crore, up 51%, while operating EBITDA increased 54% to INR1,666 crore. The 33.5% EBITDA margin remained strong despite higher R&D investment and temporary JB integration disruption, indicating substantial operating leverage and early merger benefits. India remains the principal growth engine, with Torrent’s standalone India business growing 20% against 12% IPM growth. Curatio grew 34% and now represents approximately 7%–8% of base India revenue, while semaglutide achieved 32% combined market share despite a temporary injectable supply disruption. International performance is increasingly polarized: Brazil grew strongly on price, volume and launches, while the US benefited from new products and higher filings. Germany remains weak because of tender losses, supplier disruptions and mandated price reductions, with management expecting only gradual stabilization over the next several quarters.

Over the past 52 weeks, Torrent Pharmaceuticals Ltd has traded between a low of ₹3,632.00 and a high of ₹5,249.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Torrent Pharmaceuticals Ltd has a market capitalization of approximately 1,80,332.40. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Torrent Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 85.91 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,80,332.40 Cr, Torrent Pharmaceuticals Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Torrent Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Torrent Pharmaceuticals Ltd is 85.91. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue was ₹4,921 crore and net profit (PAT) was ₹566 crore in Q1 FY27.

Revenue rose 11% year-on-year to INR 3,178 crore, while consolidated net profit increased about 20% to INR 548 crore for the quarter ended June 2025.

Torrent Pharma said the USFDA inspected its Dahej, Gujarat facility from January 19-23, 2026 and the inspection concluded with zero observations and no Form 483 issued.

Torrent Pharmaceuticals said the amalgamation became effective on July 8, 2026, after filing certified copies of the NCLT order with the Registrar of Companies.